NEWS:

Award from the Walter Schulz foundation for cancer research

Dr. Tim Lankisch, Hannover Medical School, received an award from the Walter Schulz foundation for his research in early detection of malignant biliary tract diseases.

Using capillary electrophoresis mass spectrometry (CE-MS) disease-specific peptide patterns were established enabling the distinction of benign and malignant bile duct diseases. Cholangiocarcinoma (CC) is the second most common hepatobiliary cancer. It is often detected late and at an unresectable stage.

Publication selected by Faculty of 1000

Our publication in Hepatology �Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis� has been selected and evaluated by Tom Hemming Karlsen, a Member of the Faculty of 1000 (F1000).

FEATURED ARTICLES:

Neurology

Peptide fingerprinting of Alzheimer´s disease in cerebrospinal fluid:Identification and prospective evaluation of new synaptic biomarkers
PLoS ONE 2011 Oct; 6(10): e26540

Oncology

Urinary proteome analysis for prostate cancer diagnosis: Cost-effective application in routine clinical practice in Germany
Int J Urol. 2011 Nov 22. doi: 10.1111/j.1442-2042.2011.02901.x. [Epub ahead of print]

Nephrology

Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.

MCP 2010 Jul | Read more

Methodology

Comprehensive human urine standards for comparability and standardization in clinical proteome analysis.
Proteomics Clinical Applications 2010; 4:464-478

Methodology

Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease
Journal of Proteome Research 2009; 8(1): 268-281

Cardiovascular Disease

Evaluation of Urine Proteome Pattern Analysis for Its Potential To Reflect Coronary Artery Atherosclerosis in Symptomatic Patients
Journal of Proteome Research 2009, 8(1): 335-345

Oncology

Prediction of Muscle-invasive Bladder Cancer Using Urinary Proteomics
Clin Cancer Res. 2009 Aug 1;15(15):4935-43. Epub 2009 Jul

CE-MS-Technology

Protein Analysis for Clinical Diagnosis and Pharmaceutical Research

Mosaiques diagnostics provides highly innovative Clinical Proteomics services for academic institutions and pharmaceutical companies. Mosaiques revolutionary CE-MS technology (capillary electrophoresis coupled to mass spectrometry) helps to diagnose severe diseases at an early development stage, control efficacy of applied therapies in personalized medicine, examine efficacy of new drugs in preclinical (animal models) and clinical trials and to identify therapeutic targets.

The unique CE-MS technology displays peptides and proteins of body fluids. The generated pattern filed in a database provides a fast and authentic description of the individual health of an organism. Measurement of the proteome in combination with on-line database matching is the key to an all-in-one diagnosis for a wide spectrum of clinical applications.

DiaPat GmbH, a subsidiary of mosaiques diagnostics and therapeutics AG, markets successfully new diagnostic tests in Europe for Chronic Renal Diseases (including Diabetic Nephropathy), Bladder Cancer, Prostate Cancer, Cholangiocarcinoma, Coronary Artery Disease, Ureteropelvic Junction Obstruction in Neonates and for early detection of Graft-versus-Host Disease, based on the technology described.